A systematic review of side effects of nucleoside and nucleotide drugs used for treatment of chronic hepatitis B

被引：42
作者：
Khungar V. [1 ]
Han S.-H. [1 ,2 ]
机构：
[1] Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
[2] Pfleger Liver Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095
来源：
Current Hepatitis Reports | 2010年 / 9卷 / 2期
关键词：
Adefovir dipivoxil; Chronic hepatitis B virus infection; Entecavir; Lamivudine; Nucleosides; Nucleotides; Telbivudine; Tenofovir disoproxil fumarate;
D O I：
10.1007/s11901-010-0039-1
中图分类号：
学科分类号：
摘要：
Although nucleosides and nucleotides have a good safety record for the treatment of hepatitis B, there have been no systematic reviews on this topic. We searched Medline to include studies of the oral antiviral agents for hepatitis B and adverse events, with at least 48 weeks of follow-up from the initiation of treatment with the drug. Important toxicities include nephrotoxicity, myopathy, and resistance. It is often difficult to ascertain whether an adverse effect is from the study drug or the natural progression of the disease. Further safety data are needed for the newer agents and for all agents with regard to patients with decompensated liver disease, renal dysfunction, the elderly, children, and pregnant women. © 2010 The Author(s).
引用
收藏
页码：75 / 90
页数：15
相关论文
共 47 条
  • [1] Kao J.H., Chen D.S., The natural history of hepatitis B virus infection, Hepatitis B Virus, pp. 161-172, (2002)
  • [2] Lok A.S.F., McMahon B.J., Chronic hepatitis B: Update 2009, Hepatology, 50, 3, pp. 1-36, (2009)
  • [3] EASL Clinical Practice Guidelines: Management of chronic hepatitis B, J Hepatol, 50, pp. 227-242, (2009)
  • [4] Fontana R.J., Side effects of long-term oral antiviral therapy for hepatitis B, Hepatology, 49, (2009)
  • [5] Birkus G., Hitchcock M.J., Cihlar T., Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors, Antimicrob Agents Chemo, 46, pp. 716-723, (2002)
  • [6] McKenzie R., Fried M.W., Sallie R., Et al., Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analog for chronic hepatitis B, N Engl J Med, 333, pp. 1099-1105, (1995)
  • [7] Lange C.M., Bojunga J., Hofmann W.P., Et al., Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function, Hepatology, 50, pp. 2001-2006, (2009)
  • [8] Lai C.L., Chien R.N., Leung N.W., Et al., A one-year trial of lamivudine for chronic hepatitis B, N Engl J Med, 339, pp. 61-68, (1998)
  • [9] Benhamou Y., Thibault V., Vig P., Et al., Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1, J Hepatol, 44, pp. 62-67, (2006)
  • [10] Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Et al., Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years, Gastroenterology, 131, pp. 1743-1751, (2006)
12345